Bioinvent AB licences BI-1206 to CASI Pharmaceuticals

Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region

   

Read more

Transgene reports clinical results of TG4001 plus avelumab

Transgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaA’s PD-L1 blocker avelumab.

Read more

Roche licences antiviral nucleoside from Atea

Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceutical’s oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.

Read more

ADC company Araris Biotech raises CHF15.2m

New ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates.
 
·    

Read more

Atriva Therapeutics gets €24m from EIB

Atriva Therapeutics has secured a €24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor.

Read more

Topas raises €22m in Series B financining

Topas Therapeutics GmbH will use the €22m proceeds from a Series B Financing to advance two pipeline candidates.

Read more

Siemens launches COVID-19 antigen lateral flow test

Siemens Healthineers has launched its Clinitest Rapid COVID-19 Antigen Test in Europe, which can identify persons infected with SARS-CoV-2 in 15 minutes.

Read more

Priothera closes €30m Series A financing

Priothera Ltd. wants to use €30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).

Read more

COVID-19 jab: EU signs contract with JNJ

Johnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.

Read more